Products - Renal cancer | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 43 products

Date | Title

Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
1 May 2025
Published:
23 June 2015
Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 October 2024
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 April 2024
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 January 2023
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 October 2022
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) (TA785)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 April 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 March 2022
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 September 2020
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 September 2020
Cabozantinib for untreated advanced renal cell carcinoma (TA542)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 October 2018
Tivozanib for treating advanced renal cell carcinoma (TA512)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 March 2018
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2018
Immunosuppressive therapy for kidney transplant in adults (TA481)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 August 2017
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2017
Nivolumab for previously treated advanced renal cell carcinoma (TA417)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2016
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2015
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 August 2013
Published:
23 February 2011
Irreversible electroporation for treating renal cancer (IPG443)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2013
Single-port laparoscopic nephrectomy (IPG414)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 November 2011
Laparoscopic cryotherapy for renal cancer (IPG405)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 August 2011
Percutaneous cryotherapy for renal cancer (IPG402)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 July 2011
Percutaneous radiofrequency ablation for renal cancer (IPG353)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2010
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2009
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2009
Laparoscopic partial nephrectomy (IPG151)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 January 2006
Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 August 2005
Laparoscopic live donor simple nephrectomy (IPG57)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 May 2004
Improving outcomes in urological cancers (CSG2)
Product type:
Guidance
Programme:
Cancer service guideline
Published:
19 September 2002
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
4 October 2022
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Suspected Cancer: recognition and referral
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer
Status:
In development
Expected publication date:
TBC
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [TSID12177]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC